456 related articles for article (PubMed ID: 32709873)
1. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
3. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
7. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
[TBL] [Abstract][Full Text] [Related]
9. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
Peng H; Zhang Q; Li J; Zhang N; Hua Y; Xu L; Deng Y; Lai J; Peng Z; Peng B; Chen M; Peng S; Kuang M
Oncotarget; 2016 Mar; 7(13):17220-9. PubMed ID: 26967384
[TBL] [Abstract][Full Text] [Related]
10. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
11. Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.
Xie K; Nian J; Zhu X; Geng X; Liu F
Int J Clin Exp Pathol; 2015; 8(11):14028-33. PubMed ID: 26823715
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
13. COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma.
Lang Q; Xiao P; Zhao M; Liang D; Meng Q; Pei T
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1247-1256. PubMed ID: 33166992
[TBL] [Abstract][Full Text] [Related]
14. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
15. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
16. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
He C; Wu T; Hao Y
Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
[TBL] [Abstract][Full Text] [Related]
18. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
19. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma.
Sang H; Li T; Li H; Liu J
PLoS One; 2013; 8(11):e81347. PubMed ID: 24312291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
